Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
G1 Therapeutics, Inc. | CFO | Common Stock | 57.8K | $170K | $2.94 | Jan 5, 2023 | Direct |
G1 Therapeutics, Inc. | CFO | Stock Options (Right to buy) | 44.6K | Jan 3, 2023 | Direct | ||
Viridian Therapeutics, Inc.\DE | Director | Stock Option (Right to Buy) | 21K | Jun 26, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
VRDN | Viridian Therapeutics, Inc.\DE | Jun 26, 2024 | 1 | $0 | 4 | Jun 28, 2024 | Director |
VRDN | Viridian Therapeutics, Inc.\DE | Jun 14, 2023 | 1 | $0 | 4 | Jun 16, 2023 | Director |
GTHX | G1 Therapeutics, Inc. | Jan 3, 2023 | 4 | -$13.1K | 4 | Jan 5, 2023 | CFO |
VRDN | Viridian Therapeutics, Inc.\DE | Jun 8, 2022 | 1 | $0 | 4 | Jun 10, 2022 | Director |
GTHX | G1 Therapeutics, Inc. | Feb 1, 2022 | 4 | $9.58K | 4 | Feb 2, 2022 | CFO |
GTHX | G1 Therapeutics, Inc. | Jan 3, 2022 | 3 | -$15.3K | 4 | Jan 5, 2022 | CFO |
VRDN | Viridian Therapeutics, Inc.\DE | Jul 14, 2021 | 1 | $0 | 4 | Jul 15, 2021 | Director |
VRDN | Viridian Therapeutics, Inc.\DE | Jul 14, 2021 | 0 | $0 | 3 | Jul 15, 2021 | Director |